Literature DB >> 22961984

A sequential mechanism for exosite-mediated factor IX activation by factor XIa.

Yipeng Geng1, Ingrid M Verhamme, Amanda Messer, Mao-fu Sun, Stephen B Smith, S Paul Bajaj, David Gailani.   

Abstract

During blood coagulation, the protease factor XIa (fXIa) activates factor IX (fIX). We describe a new mechanism for this process. FIX is cleaved initially after Arg(145) to form fIXα, and then after Arg(180) to form the protease fIXaβ. FIXα is released from fXIa, and must rebind for cleavage after Arg(180) to occur. Catalytic efficiency of cleavage after Arg(180) is 7-fold greater than for cleavage after Arg(145), limiting fIXα accumulation. FXIa contains four apple domains (A1-A4) and a catalytic domain. Exosite(s) on fXIa are required for fIX binding, however, there is lack of consensus on their location(s), with sites on the A2, A3, and catalytic domains described. Replacing the A3 domain with the prekallikrein A3 domain increases K(m) for fIX cleavage after Arg(145) and Arg(180) 25- and ≥ 90-fold, respectively, and markedly decreases k(cat) for cleavage after Arg(180). Similar results were obtained with the isolated fXIa catalytic domain, or fXIa in the absence of Ca(2+). Forms of fXIa lacking the A3 domain exhibit 15-fold lower catalytic efficiency for cleavage after Arg(180) than for cleavage after Arg(145), resulting in fIXα accumulation. Replacing the A2 domain does not affect fIX activation. The results demonstrate that fXIa activates fIX by an exosite- and Ca(2+)-mediated release-rebind mechanism in which efficiency of the second cleavage is enhanced by conformational changes resulting from the first cleavage. Initial binding of fIX and fIXα requires an exosite on the fXIa A3 domain, but not the A2 or catalytic domain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22961984      PMCID: PMC3488089          DOI: 10.1074/jbc.M112.376343

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

Review 1.  Exosite-driven substrate specificity and function in coagulation.

Authors:  S Krishnaswamy
Journal:  J Thromb Haemost       Date:  2005-01       Impact factor: 5.824

Review 2.  Determinants of specificity in coagulation proteases.

Authors:  M J Page; R T A Macgillivray; E Di Cera
Journal:  J Thromb Haemost       Date:  2005-11       Impact factor: 5.824

3.  Exosite-mediated substrate recognition of factor IX by factor XIa. The factor XIa heavy chain is required for initial recognition of factor IX.

Authors:  Taketoshi Ogawa; Ingrid M Verhamme; Mao-Fu Sun; Paul E Bock; David Gailani
Journal:  J Biol Chem       Date:  2005-04-13       Impact factor: 5.157

Review 4.  The tissue factor pathway of blood coagulation.

Authors:  Y Nemerson
Journal:  Semin Hematol       Date:  1992-07       Impact factor: 3.851

5.  Crystal structure of the factor XI zymogen reveals a pathway for transactivation.

Authors:  Evangelos Papagrigoriou; Paul A McEwan; Peter N Walsh; Jonas Emsley
Journal:  Nat Struct Mol Biol       Date:  2006-05-14       Impact factor: 15.369

6.  Regions remote from the site of cleavage determine macromolecular substrate recognition by the prothrombinase complex.

Authors:  A Betz; S Krishnaswamy
Journal:  J Biol Chem       Date:  1998-04-24       Impact factor: 5.157

7.  Factor IX activation by factor XIa proceeds without release of a free intermediate.

Authors:  A S Wolberg; D P Morris; D W Stafford
Journal:  Biochemistry       Date:  1997-04-08       Impact factor: 3.162

8.  Binding of substrate in two conformations to human prothrombinase drives consecutive cleavage at two sites in prothrombin.

Authors:  Steven J Orcutt; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2004-10-19       Impact factor: 5.157

Review 9.  Exosites in the substrate specificity of blood coagulation reactions.

Authors:  P E Bock; P Panizzi; I M A Verhamme
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

10.  Identification and chemical synthesis of a substrate-binding site for factor IX on coagulation factor XIa.

Authors:  F A Baglia; B A Jameson; P N Walsh
Journal:  J Biol Chem       Date:  1991-12-15       Impact factor: 5.157

View more
  18 in total

1.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 2.  Factor XI and contact activation as targets for antithrombotic therapy.

Authors:  D Gailani; C E Bane; A Gruber
Journal:  J Thromb Haemost       Date:  2015-06-16       Impact factor: 5.824

3.  The evolution of factor XI and the kallikrein-kinin system.

Authors:  Michał B Ponczek; Aleksandr Shamanaev; Alec LaPlace; S Kent Dickeson; Priyanka Srivastava; Mao-Fu Sun; Andras Gruber; Christian Kastrup; Jonas Emsley; David Gailani
Journal:  Blood Adv       Date:  2020-12-22

4.  Factor XI anion-binding sites are required for productive interactions with polyphosphate.

Authors:  Y Geng; I M Verhamme; S A Smith; Q Cheng; M Sun; J P Sheehan; J H Morrissey; D Gailani
Journal:  J Thromb Haemost       Date:  2013-11       Impact factor: 5.824

Review 5.  Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present).

Authors:  Rami A Al-Horani
Journal:  Expert Opin Ther Pat       Date:  2019-12-19       Impact factor: 6.674

6.  Evidence for factor IX-independent roles for factor XIa in blood coagulation.

Authors:  A Matafonov; Q Cheng; Y Geng; I M Verhamme; O Umunakwe; E I Tucker; M-F Sun; V Serebrov; A Gruber; D Gailani
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

7.  Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen.

Authors:  Ivan Ivanov; Ruhama Shakhawat; Mao-Fu Sun; S Kent Dickeson; Cristina Puy; Owen J T McCarty; Andras Gruber; Anton Matafonov; David Gailani
Journal:  Thromb Haemost       Date:  2017-01-26       Impact factor: 5.249

8.  Generation and characterization of aptamers targeting factor XIa.

Authors:  R S Woodruff; I Ivanov; I M Verhamme; M-F Sun; D Gailani; B A Sullenger
Journal:  Thromb Res       Date:  2017-06-09       Impact factor: 3.944

Review 9.  Factor XI as a target for antithrombotic therapy.

Authors:  Charles E Bane; David Gailani
Journal:  Drug Discov Today       Date:  2014-06-02       Impact factor: 7.851

Review 10.  Haemophilia.

Authors:  Erik Berntorp; Kathelijn Fischer; Daniel P Hart; Maria Elisa Mancuso; David Stephensen; Amy D Shapiro; Victor Blanchette
Journal:  Nat Rev Dis Primers       Date:  2021-06-24       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.